Samjo Management LLC Has $4.32 Million Holdings in MDxHealth SA (NASDAQ:MDXH)

Samjo Management LLC boosted its position in MDxHealth SA (NASDAQ:MDXH) by 130.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,824,312 shares of the company’s stock after buying an additional 1,034,312 shares during the period. MDxHealth makes up 1.6% of Samjo Management LLC’s holdings, making the stock its 19th biggest holding. Samjo Management LLC’s holdings in MDxHealth were worth $4,324,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the company. Perkins Capital Management Inc. increased its holdings in MDxHealth by 31.6% in the fourth quarter. Perkins Capital Management Inc. now owns 983,475 shares of the company’s stock worth $2,331,000 after purchasing an additional 236,100 shares in the last quarter. Oppenheimer & Co. Inc. boosted its stake in MDxHealth by 100.0% during the fourth quarter. Oppenheimer & Co. Inc. now owns 20,000 shares of the company’s stock worth $47,000 after acquiring an additional 10,000 shares in the last quarter. Maven Securities LTD acquired a new stake in MDxHealth in the third quarter worth $208,000. Finally, Geode Capital Management LLC acquired a new stake in MDxHealth in the fourth quarter worth $25,000.

MDxHealth Price Performance

Shares of NASDAQ MDXH opened at $1.48 on Friday. The firm has a market capitalization of $69.99 million, a P/E ratio of -0.97 and a beta of 1.37. The firm’s 50-day moving average price is $1.70 and its 200-day moving average price is $1.96. The company has a current ratio of 1.54, a quick ratio of 1.45 and a debt-to-equity ratio of 3.14. MDxHealth SA has a 1-year low of $1.35 and a 1-year high of $3.50.

MDxHealth (NASDAQ:MDXH) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.07. The business had revenue of $24.74 million for the quarter, compared to analyst estimates of $22.67 million. MDxHealth had a negative return on equity of 1,077.84% and a negative net margin of 49.52%. Equities research analysts anticipate that MDxHealth SA will post -1.15 earnings per share for the current fiscal year.

MDxHealth Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.